Market Overview - The Hong Kong stock market for innovative drugs has seen a strong rebound in 2023, with the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index (HSSCPB) achieving a year-to-date increase of 71.83%, contrasting sharply with a decline of 20.74% in the same period last year [1] - The Hong Kong innovative drug ETF (159567) also recorded a significant growth of 67.16% [1] - The ongoing recovery in the secondary market has created new opportunities for numerous pharmaceutical companies seeking to go public, leading to a surge in IPO activity in Hong Kong [1] IPO Activity - In June alone, seven local pharmaceutical companies, including Hansai Aitai, Weili Zhibo, Yinnuo Pharmaceutical, Dongyangguang Pharmaceutical, Changfeng Pharmaceutical, Hemei Pharmaceutical, and Xuanzhu Biological, have submitted applications for listing in Hong Kong [1] - Notably, several of these companies, such as Hansai Aitai, Weili Zhibo, Yinnuo Pharmaceutical, Hemei Pharmaceutical, and Xuanzhu Biological, are still in a loss-making state [1] - The trend of companies transitioning from A-share IPO attempts to Hong Kong listings is evident, as seen with Changfeng Pharmaceutical and Xuanzhu Biological [1] Financial Performance of IPO Candidates - Hansai Aitai reported revenues of 6.664 million yuan and 7.681 million yuan for 2023 and 2024, respectively, with losses of 85.16 million yuan and 116.92 million yuan [2] - Weili Zhibo's revenue for 2023 was 8.865 million yuan, with losses of 36.2249 million yuan and 30.1216 million yuan for 2023 and 2024 [2] - Yinnuo Pharmaceutical generated revenues of 16.849 million yuan and 20.055 million yuan for 2023 and 2024, with losses of 73.3376 million yuan and 17.469 million yuan [2] Industry Trends - The Hong Kong IPO market is becoming increasingly attractive for Chinese pharmaceutical companies due to more flexible and lenient listing conditions compared to the A-share market [2] - The introduction of the "18A" listing rule in 2018 has opened doors for unprofitable biotech companies, fueling the IPO wave among innovative drug companies [3] - The current phase of the pharmaceutical industry is characterized by a "structural thaw," where companies with genuine innovation are beginning to attract financing [3] Challenges for Innovative Drug Companies - Many companies, including Hansai Aitai, face significant challenges due to high R&D costs and prolonged timelines for drug development [4] - The average success rate for drug development from Phase I to FDA approval is only 7.9%, with a lengthy average timeline of 10.5 years [4] - Companies like Weili Zhibo are also navigating uncertainties, having lost significant business development (BD) projects just before their IPO [6] Competitive Landscape - Companies with commercialized products, such as Yinnuo Pharmaceutical and Xuanzhu Biological, are also facing intense market competition and product iteration pressures [8] - Yinnuo Pharmaceutical's flagship product, approved for treating type 2 diabetes, has not yet turned the company profitable, with losses of 73.3 million yuan and 17.5 million yuan projected for 2023 and 2024 [8] - Dongyangguang Pharmaceutical, despite its market leadership, is confronting risks associated with expiring patents, particularly for its key product [9] Strategic Focus - Dongyangguang Pharmaceutical aims to enhance operational efficiency and explore new growth avenues through the integration of its R&D platform and product pipeline [9] - Changfeng Pharmaceutical plans to invest raised funds into the full-cycle R&D and commercialization of inhalation formulations, as well as upgrading production facilities [9] - The overall expectation is that both loss-making and established companies will leverage the Hong Kong listing to navigate the competitive landscape of the biopharmaceutical industry [10]

【深圳商报讯】（记者钟国斌）作为A股调味品行业龙头企业，海天味业近日启动港股全球发售相关工 作，本次发售时间为6月11日至16日，发售价格35港元/股至36.3港元/股，最高募资总额约95.6亿港元， 成为年内港股市场最大规模IPO之一。6月19日，海天味业H股在港交所主板上市。 海天味业赴港上市吸引了众多投资者踊跃参与，其中基石投资者认购金额近47亿港元，认购份额约占总 发售股份的50%。这一数据不仅创下年内基石投资者认购规模的新高，也充分展现出国际资本对中国消 费行业龙头企业的高度认可。 业内人士表示，此次IPO将成为港股2023年以来继宁德时代、美的集团港股IPO后，基石投资者认购规 模第三大的IPO。 公开资料显示，海天味业成立于2000年，前身是1955年佛山25家古酱园合并重组而成的"海天酱油厂"。 按销量计算，截至2024年，海天味业已连续28年蝉联国内最大调味品企业。按2024年收入计算，海天味 业在国内调味品市场中排行首位，在全球调味品市场中排名第五；酱油、蚝油产品销量连续多年位居国 内调味品市场第一。 （文章来源：深圳商报） 2014年，海天味业在A股上市。上市以来，海天味业展现出强劲的增 ...

Core Viewpoint - EVE Energy aims to maintain its position as a "second-tier leader" in the lithium battery industry and effectively counter "black swan" events by proactively gathering funding sources [1][9][60] Group 1: IPO and Market Response - EVE Energy's announcement of its H-share IPO on the Hong Kong Stock Exchange did not receive a warm response from the capital market, unlike CATL [2][4] - Following the IPO announcement, EVE Energy's A-share price fell nearly 5% from 45.02 CNY to 42.78 CNY [3] - The muted market reaction is attributed to the slowdown in the lithium battery industry and investor concerns over the company's potential funding pressures [6] Group 2: Funding Needs and Global Expansion - The funds raised from the Hong Kong IPO are crucial for EVE Energy, described as a "lifeline" for the company [7] - EVE Energy plans to use the IPO proceeds for overseas factory construction, accelerating global capacity layout, and supplementing working capital [11] - The company has a cash balance of approximately 13.4 billion CNY, but its overseas projects require nearly 17.4 billion CNY, leaving a funding gap of about 4 billion CNY [19] Group 3: Customer Payment Challenges - EVE Energy's core business, power batteries, accounts for nearly 40% of its revenue, with automotive companies as its primary customers [25] - Following the IPO announcement, several automotive companies committed to reducing payment terms to within 60 days, highlighting a significant change in the supply chain [26] - The average accounts payable turnover days for domestic automakers is 171.6 days, significantly higher than the less than 60 days typical for Western brands [28] Group 4: Storage Battery Market and Competition - EVE Energy's storage battery revenue is projected to account for 39.14% of total revenue in 2024, with a shipment target of 50.45 GWh, making it the second-largest globally after CATL [36] - The U.S. market is a key target for EVE Energy, but changes in policy, such as the IRA, pose significant challenges for its downstream customers [38][39] - The bankruptcy of Powin, a major U.S. energy storage integrator and customer, raises concerns about future cooperation and payment uncertainties [40][43] Group 5: R&D Investment and Competitive Pressure - EVE Energy must invest heavily in R&D to keep pace with competitors, with R&D spending increasing from 700 million CNY to 2.942 billion CNY over the past five years [47] - The company plans to launch a pilot line for solid-state batteries by the end of this year, aiming for a 400 Wh/kg energy density by 2028, which lags behind competitors [49][55] - EVE Energy faces intense competition in large-capacity battery cells, with rivals rapidly advancing their technologies [56][58] Group 6: Overall Challenges and Future Outlook - EVE Energy is confronted with multiple challenges, including the need for funding for overseas expansion, risks in accounts receivable, difficulties in the storage market, and pressures from R&D investments [59] - The success of the Hong Kong IPO is critical not only for expanding financing channels but also for supporting overseas expansion and technological advancements [60]

6月11日至12日，由证券时报社与香港公司治理公会联合主办、德勤中国支持的"香港IPO辅导公开课 程"在杭州玉皇山基金小镇路演中心圆满举行。此次课程汇聚行业顶尖资源，吸引近200名上市及拟上市 公司高管参与，为内地企业拥抱港股资本市场搭建了专业交流平台。香港公司治理公会北京代表处首席 代表高伟博士担纲主持。 香港作为国际金融中心，拥有高度开放的资本市场，截至2024年底，香港市场上市公司总数已突破2600 家，总市值连续多年位列全球前五大资本市场。2024年，港股70多家公司实现上市，数量呈数倍增长， 其中内地企业占比超九成，彰显了双循环格局下资本要素的高效流动。 据数据统计，2014年至2024年，香港IPO累计募集资金领跑全球，达3030亿美元，超过纳斯达克和纽交 所。此外，新经济、科技企业引领近年香港IPO市场，2018年至2024年，IPO募资额占比最高前五大行 业分别为资讯科技、消费、医疗保健、地产建筑、金融。 作为资本市场的深度参与者与忠实记录者，证券时报始终坚守专业权威定位，持续为企业与投资者提供 价值服务。活动现场，证券时报华东一部主任张霞在致辞中强调，证券时报不断深化对港股市场的关注 与研究 ...

中国工商银行(亚洲)证券业务部分析员叶泽恒接受中新社记者采访时表示，今年以来，港股集资金额按 年显著增加，当中不乏大型内地企业。目前，有不少大型企业已向香港交易及结算所有限公司(简称"香 港交易所")递交初步招股文件，若市场反应理想兼再有资金流入，估计对香港交易所及证券行业板块有 正面作用。(完) （文章来源：中国新闻网） 中新社香港6月13日电 (记者戴小橦)13日，香港恒生指数收报23892.56点，当周累计上涨0.42%；恒生科 技指数当日收报5239.71点，当周累计下跌0.89%；国企指数当日收报8655.33点，当周累计上涨0.3%。 当周，港股市场平均每日成交额逾2500亿港元，按周增加23.2%。 会计师事务所安永12日发布的2025年上半年《中国内地和香港IPO市场》报告称，香港市场今年上半年 预计约40家公司首发上市，募资额约1087亿港元，首次公开募股(IPO)数量和募资额分别同比上涨33% 和711%，占全球新股市场24%，暂列全球首位。今年上半年的募资额预计将超过去年全年，香港IPO平 均募资额同比上涨超5倍，近10年内仅次于2021年同期。 安永香港资本市场服务发言人赖耘峯表示，预 ...

Core Viewpoint - Huada Beidou has submitted its IPO application to the Hong Kong Stock Exchange, facing challenges due to unstable revenue and significant losses over the past three years [1][5]. Group 1: Financial Performance - Huada Beidou's revenue over the past three years has been inconsistent, with total revenues of RMB 698 million, RMB 645 million, and RMB 840 million for 2022, 2023, and 2024 respectively [9]. - The company has incurred cumulative losses exceeding RMB 500 million over the past three years, with annual losses of RMB 93 million, RMB 289 million, and RMB 141 million for the respective years [9]. - The gross profit margin has been declining, with rates of 12%, 10.5%, and 9.8% over the same period, significantly lower than comparable companies [10][11]. Group 2: Revenue Sources - Over 70% of Huada Beidou's revenue is derived from distribution business, which has a low gross margin in the single digits, leading to a lower overall gross margin compared to industry peers [1][10]. - The revenue from GNSS chips and related solutions accounted for 27.7%, 26%, and 28.3% of total revenue in the last three years, while the comprehensive chip and module business contributed 72.3%, 74%, and 71.7% [6]. Group 3: Market Position - In 2024, Huada Beidou shipped 16.1 million GNSS chips and modules, ranking as the sixth largest GNSS service provider globally and the second largest among Chinese companies, with a market share of 4.8% [4]. - The company is the largest provider of dual-frequency high-precision GNSS chips and modules in China, with a market share of 10.5% [4]. Group 4: IPO Process and Challenges - Huada Beidou's IPO journey has faced multiple setbacks, including a terminated agreement with CITIC Securities in 2023 and a lack of progress updates on its current advisory process [4][5]. - The company has expressed intentions to explore various capital market strategies, including a potential IPO in Hong Kong [5]. Group 5: Disclosure Issues - There are significant discrepancies between the procurement data disclosed in Huada Beidou's prospectus and the sales figures reported by suppliers, raising concerns about the accuracy of financial disclosures [12][15]. - The largest supplier, Aojie Technology-U, has reported sales figures that do not align with Huada Beidou's procurement amounts, indicating potential issues with revenue recognition [14][15].

Market Overview - The Hong Kong stock market opened lower on June 13, with the Hang Seng Index down 0.31%, the Hang Seng Tech Index down 0.95%, and the National Enterprises Index down 0.47% [1] - Technology stocks showed mixed performance, with Sunny Optical Technology rising by 0.45% while Alibaba fell by over 1% [1] Market Sentiment and Predictions - Huatai Securities believes that the Hong Kong stock market has strategic allocation value in the medium to long term, driven by factors such as corporate overseas expansion, capital repatriation, and RMB internationalization [1] - The market's driving force in the second half of the year is expected to come from profit growth, although volatility may remain high in Q3, with high-dividend sectors and essential consumer goods recommended for core allocation [1] - CICC noted that the Hong Kong market significantly outperformed the A-share market in the first half of the year, but the rebound has been characterized by "impulse-style" surges followed by pullbacks, with only about 35% of stocks outperforming the index [1] - CICC anticipates that the Hong Kong market will face an "asset shortage" situation due to excess liquidity and limited returns, predicting a range-bound index with structural market trends remaining the main focus [1] - Guotai Junan pointed out that despite a lack of upward elasticity at the macro level, profound changes are occurring at the industrial level, with new consumption and AI applications likely to attract market attention [1] IPO Market Activity - Ernst & Young reported a significant increase in Hong Kong's IPO activity, with the number of IPOs and fundraising amounts rising by 33% and 711% year-on-year, respectively, driven by large IPOs [3] - The report predicts that the enthusiasm for A-share companies listing in Hong Kong, the launch of the "Special Line for Science and Technology Enterprises," and the return of Chinese concept stocks will continue to boost the IPO market [3] Company News - Sunny Optical Technology reported a decrease in mobile phone lens shipments by 5.2% year-on-year to 98.1 million units in May, while automotive lens shipments increased by 28.4% year-on-year to 10.7 million units [5] - New China Life Insurance plans to invest no more than 15 billion HKD in subscribing to the third phase of a private equity fund, focusing on large listed companies in the CSI A500 index [5] - Jianye Industrial issued a profit warning, expecting a net loss attributable to shareholders of approximately 560 to 580 million HKD for the year [6] - China Resources Land reported a cumulative contract sales amount of approximately 86.85 billion HKD in the first five months, a decrease of 6.3% year-on-year [6]

Group 1 - The core viewpoint is that China International Capital Corporation (CICC) has emerged as the leading underwriter in the Hong Kong IPO market this year, with a significant number of deals and underwriting amounts [1][2] - As of June 12, CICC has sponsored 9 IPOs, ranking first among all underwriters, followed by China Merchants International with 5 IPOs [1] - The total amount raised through IPOs in Hong Kong this year reached 77.346 billion HKD, nearing the total amount raised in the previous year [1] Group 2 - In terms of underwriting amounts, CICC leads with a total of 18.679 billion HKD from 13 IPOs, followed by other major players like Merrill and JPMorgan [2] - Over 40 companies are currently planning to list in Hong Kong, with more than 20 already having submitted applications to the Hong Kong Stock Exchange [2] - There is a notable trend of Chinese securities firms accelerating their international expansion, with 36 firms having established international subsidiaries in Hong Kong [2]

Core Viewpoint - The strong willingness of issuers to list in Hong Kong has led to a surge in IPOs, with over 40 companies announcing plans to go public this year, matching the total from the past 20 years [1][4] Group 1: Factors Driving IPO Surge - Three main factors are contributing to the increased activity in Hong Kong IPOs: 1. China's economic stimulus policies have heightened global investor interest in Chinese assets, particularly in the AI sector [5][6] 2. Regulatory support from both mainland China and Hong Kong has expedited the IPO process [5] 3. The quality of companies going public has improved, sustaining high investor enthusiasm for new listings [5][6] Group 2: Market Dynamics - The participation of long-term funds in IPOs has significantly increased, with the number of international long-term funds involved in a single IPO rising from 3-5 to over 20 [8][10] - Notable IPOs include CATL, which raised approximately 41 billion HKD, and other companies like Hengrui Medicine and Mx Group also achieving substantial fundraising [4][8] Group 3: New Regulations and Market Opportunities - New regulations allow companies listed in Hong Kong from the Greater Bay Area to also list on the Shenzhen Stock Exchange, promoting capital flow between the two markets [1][11] - Approximately 250 companies listed in Hong Kong are registered in the Greater Bay Area, with 30 already listed in A-shares, indicating potential for further listings [12]

东阳光药业是一家综合性制药公司，主要从事药物的研发、生产和商业化。公司战略性地专注于感染、 慢病及肿瘤等治疗领域，在中国生产药物并主要在中国销售药品。截至最后实际可行日期，公司在中国 销售48款药物，并在海外市场销售23款药物。 6月11日，广东东阳光药业股份有限公司（以下简称"东阳光药业"）向港交所提交上市申请书，独家保 荐人为中国国际金融香港证券有限公司。 然而，公司目前面临两大主要风险：首先，公司收入和盈利能力过度依赖抗流感药物可威®（磷酸奥司 他韦）。2022-2024年，磷酸奥司他韦的销售额分别占公司总收入的81.2%、86.9%和64.2%。其次，可 威®的销售受流感发病率影响显著且具有明显的季节性，导致公司收入波动较大。例如，2024年由于中 国流感发病率下降，公司可威®销售额较2023年大幅下滑。 公司拥有完善的研发平台和生产体系。公司拥有超过1,100名研发人员，研发平台覆盖化学药及生物药 完整生命周期。公司的生产设施已获得中国、美国和欧洲的GMP认证，拥有四处生产基地，总建筑面 积约301,160平方米，设有16个主要生产车间。公司在中国抗病毒药物市场占据领先地位，以销售收入 计过去五年在 ...